Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25584235 | 0.81 | KCNH2 (0.41) | KCNH2PARP1SIGMAR1MAP4K4EGLN2 | |
| SCHEMBL22267933 | 0.78 | HRH4 (0.42) | KCNH2HRH4HRH3SIGMAR1 | |
| SCHEMBL23608973 | 0.78 | SIGMAR1 (0.35) | KCNH2HRH3SIGMAR1 | |
| SCHEMBL16221899 | 0.77 | VNN1 (0.41) | VNN1CD274 | |
| SCHEMBL25584191 | 0.75 | MAP4K4 (0.52) | KCNH2PARP1MAP4K4SLC2A1 | |
| SCHEMBL104748 | 0.75 | CYP1A2 (0.62) | LTA4H | |
| SCHEMBL20069151 | 0.75 | KCNH2 (0.46) | KCNH2DYRK1A | |
| SCHEMBL31226682 | 0.74 | KCNH2 (0.45) | KCNH2DYRK1APARP1MAP4K4SLC2A1 | |
| SCHEMBL17827395 | 0.74 | KCNH2 (0.45) | KCNH2DYRK1APARP1EGLN2SLC2A1 | |
| SCHEMBL18252807 | 0.74 | KCNH2 (0.45) | KCNH2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220089571-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-07-01 | — | — | US | disclosed |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-02-16 | — | — | US | disclosed |
| WO-2020150113-A1 | SUBSTITUTED QUINAZOLINES AS NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-1324985-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1324985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028831-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | KCNH2 3689/4885DYRK1A 4438/4885VNN1 563/4885 |
| US-20220089571-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | KCNH2 3999/4885DYRK1A 4866/4885VNN1 4591/4885 |
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | KCNH2 3984/4885DYRK1A 4867/4885VNN1 4531/4885 |
| US-10919888-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | KCNH2 3689/4885DYRK1A 4438/4885VNN1 563/4885 |
| US-20210198254-A1 | BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION | BET1, BRD4, BRD3 | KCNH2 3689/4885DYRK1A 4438/4885VNN1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.